HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy

Residual Viraemia in HIV-1-Infected Patients with Plasma Viral Load ≤20 copies/ml is Associated with Increased Blood Levels of Soluble Immune Activation Markers

(2010) S. R. Ostrowski et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

(2009) J. B. Dinoso et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism

(2008) Stéphanie Raymond et al.   AIDS

Blood Monocytes Harbor HIV Type 1 Strains with Diversified Phenotypes Including Macrophage‐Specific CCR5 Virus

(2008) Younong Xu et al.   JOURNAL OF INFECTIOUS DISEASES

Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells

(2008) Gautam K. Sahu et al.   JOURNAL OF MEDICAL VIROLOGY

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

(2008) S. Palmer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HIV-1 Infection of Bone Marrow Hematopoietic Progenitor Cells and Their Role in Trafficking and Viral Dissemination

(2008) Aikaterini Alexaki et al.   PLoS Pathogens